The Bulk Actives division has the technology to manufacture 40 products. With facilities that consist of four plants capable of producing a range of bulk actives (APIs), plans are afoot for major expansion over the next five years. The bulk actives division which operates as a Strategic Business Unit - the Chemicals SBU - is headquartered at Ankleshwar, Gujarat and is among the fastest growing manufacturing units with ambitious plans for the future.

This unit is spread on a 42,000 sq. mt. Plot in the GIDC chemicals zone of which 7,200 sq. mt is the constructed area, leaving ample scope for expansion.

The new Multi Purpose Plant, built at a cost of Rs.3 Millions, was executed by internationally renowned consultants - Jacobs H&G, U.K.

The state-of-the-art plant, spread over an area of 30,000 sq. ft. area is equipped to manufacture four different products simultaneously on a campaign basis, under class 100, 000 "Clean room" condition. Besides being a 'closed' plant with forced ventilation system, it also deploys scrubbing system for Acidic and Alkaline vapors, ensuring clean environment.

The APIs manufacturing facility of Cadila Pharmaceuticals group at Ankleshwar encompasses one of the highest capacities in India to produce Loratadine (Anti-Histaminic), Glibenclamide (Anti-diabetic) and Chloro Hexidine Base (Dis-infectant). The Ethambutol and the Fluoxetine plants at Cadila Pharma, Ankleshwar, are approved by USFDA.

Cadila Pharmaceuticals has an arrangement (DMF) with Mallinckrodt Inc USA, for supplying 8 APIs, including Ethambutol and Fluoxetine to them. Mallinckrodt Inc, in turn, can convert these bulks into formulations.

Fluoxetine is an anti-depressant and Cadila Pharmaceuticals has a capacity to produce 1000 kgs/month at its Ankleshwar unit. The USFDA approval to Cadila Pharma has come without any 483 comments, which shows the competency of the group in its facilities, documentations etc.

Active Pharmaceutical Ingredients manufactured at Cadila Pharmaceuticals Limited- Ankleshwar